Perceptive Discovery becomes the first US provider able to support At-211 studies, expanding access to specialized radiopharmaceutical development infrastructure through its collaboration with Atley Solutions

BOSTON, Oct. 16, 2026 /PRNewswire/ — Perceptive Discovery today announced the availability of astatine-211 (At-211) radiopharmaceutical development studies at its US and UK locations, becoming the first US provider able to execute At-211 studies.

The milestone builds on Perceptive Discovery’s strategic collaboration with Atley Solutions and expands access to specialized infrastructure and scientific expertise for biotech and pharmaceutical companies developing next-generation targeted alpha therapies.

At Perceptive Discovery’s laboratory at Queen Mary University of London (QMUL), the first Atley C100 module within the collaboration has been installed and successfully used to purify At-211 from an irradiated bismuth-209 target. In the US, At-211 delivered in solution is available from multiple sources, enabling the team to begin supporting US studies immediately with confidence around isotope supply. A second Atley C100 module is expected to be installed at Perceptive Discovery’s Needham, Massachusetts facility later this month, further expanding the company’s At-211 development capabilities.

With these capabilities now available, sponsors can access specialized At-211 radiochemistry expertise and infrastructure alongside Perceptive Discovery’s broader preclinical and translational radiopharmaceutical development capabilities.

Expanding Access to At-211 Development

At-211 is an emerging alpha-emitting radionuclide with significant potential for targeted radiopharmaceutical therapies. However, limited access to specialized infrastructure and radiochemistry expertise has been a barrier to broader development.

Perceptive combines At-211 access with established radiopharmaceutical development expertise, including:

• Internal radiolabeling experience across proteins, peptides, and small molecules
• Multiple precursor chemistries, including boronic acid, boronic ester, tributyl tin, and trimethyl tin approaches
• Analytical characterization using radio-iTLC and HPLC-based methods
• Dedicated At-211 development infrastructure through Perceptive Discovery’s collaboration with Atley Solutions, including an operational Atley C100 module at QMUL and planned expansion to the US
• Integration with preclinical imaging, biodistribution, dosimetry, efficacy, and translational development capabilities

“The ability to execute At-211 studies across our UK and US operations represents an important expansion of what we can offer sponsors developing targeted alpha therapies,” said Ben Murphy, CEO of Perceptive Discovery. “The installation and successful testing of the first Atley C100 module marks an important milestone in our collaboration with Atley. By combining access to At-211 with our established expertise in radiochemistry, in vivo imaging, oncology models, dosimetry, assay development, and translational radiopharmaceutical workflows, we can help sponsors generate the decision-ready data needed to advance promising programs toward the clinic.”

The Atley C100 is an automated manufacturing platform purpose-built for At-211 radiopharmaceuticals. The successful deployment of the first module at Perceptive Discovery’s QMUL site, together with planned installation of a second module at the company’s Needham facility, provides a foundation for expanding dedicated infrastructure to support the growing number of biotechnology and pharmaceutical companies exploring At-211-based targeted alpha therapies.

“The availability of these systems marks an important next step in our collaboration with Perceptive Discovery,” said Milton Lönnroth, CEO of Atley Solutions. “Establishing dedicated At-211 infrastructure in the US and UK expands access for developers and helps create the foundation needed to advance the next generation of At-211 radiopharmaceuticals.”

Perceptive Discovery is now accepting inquiries for At-211 development programs at its US and UK locations.

About Atley Solutions

Atley Solutions is a global leader in commercial products and services for the development and manufacturing of At-211 radiopharmaceuticals. The Atley C100 is a commercial module for automated manufacturing of At-211 radiopharmaceuticals. Atley also provides radiopharmaceutical development services and targetry for At-211 manufacturing.

For more information, visit www.atley.com.

About Perceptive Discovery

Perceptive Discovery delivers advanced preclinical and translational solutions that help sponsors generate the evidence needed to move promising therapeutics toward the clinic. With expertise spanning radiochemistry, in vivo imaging, oncology and CNS models, dosimetry, assay development, and radioligand therapy, Perceptive Discovery supports critical development decisions from early discovery through clinical translation.

For more information, visit www.perceptive.com/about-perceptive-discovery.

View original content to download multimedia:https://www.prnewswire.com/news-releases/perceptive-discovery-launches-astatine-211-study-capabilities-in-the-us-and-uk-302910710.html

SOURCE Perceptive Discovery